Bioregnum, Special

These 300(+) Biotech Twitter citizens are the quickest to tweet news


Bioregnum Bioregnum

Like many of you, I have a complicated relationship with Twitter. I don’t feel good at it, but here I am obsessing over it. I resent feeling like I need to be good at it. That’s a bad way to feel about a relationship you’ve been in for seven years.

Your friends have more friends than you do — this is the rub of social networking. There isn’t a professional I know who is proud of the small size of their Rolodex. It’s no wonder so many in biopharma join Twitter only to abandon it after a few tweets. The default state of their new account advertises to the world that nobody at all follows what you have to say. That doesn’t feel good either.

If you work inside biopharma, I’ll admit there’s not much reason for you to post to Twitter. Yes, there are exceptions and many enjoy a richer career as a result. But it’s not true for a big majority. Most knowledge in biopharma is held in the minds and experiences of people and companies. These are not shared in public.

The beauty of Twitter is that you don’t have to say anything at all.

Read-only Twitter

The dirty secret of Twitter is that it’s dependent on journalists and professional content-creators. We go to Facebook to see timelines of our friends and family. LinkedIn timelines only matter if you’re on a job hunt or recruiting people yourself.

Serious news hounds turn to Twitter because it’s the only serious place to craft a hard news timeline. And it turns out “read-only Twitter” is quite an amazing product. When you tune into the conversations of others, you learn things you didn’t know you needed to know.

Journalists, brands, and bots all rush to post content the moment it’s fit for consumption. Some links have legs, others don’t. It’s an operating system for the dissemination of news and the meta-commentary that follows. This is the top of the public info pyramid. From here these things filter downstream to the 80% of the industry who have no relationship with Twitter.

Plugging your ear into the top of this nerve center gets you closer and faster to this information. Whether this information is good or bad, that’s for you to decide. Like the telephone game, where you tell someone something and it changes downstream, your information is purer the closer it was to the signal. It’s without the color. No analog degradation.

Too much noise

Having asymmetric information is a huge advantage in business, right? You know something somebody else doesn’t, and they don’t have access to those bit of info. This is how it worked in 1990.

In 2016 you can possess asymmetric information that’s freely available to all, but was lost in the digital ether of tweets, press releases, algospam, and Native Ӓdvertising. Information is easily buried in the content swamp. You just can’t see it all.

Now there’s plenty of firms who’ll charge a $10,000 monthly retainer to sift through these tweets, travel obscure parts of the web, travel behind the paywalls, send you a summary, make sure things don’t fall through the cracks. A few lucky biopharma executives enjoy these perks.

What if you’re brand new to biopharma? How about if you’re a seasoned vet but just new to Twitter? How do you know who to follow? Twitter for all intents and purposes is a consumer brand. Despite it being a rich, immediate source of information for drug developers, Twitter the company has no products to onboard such a niche audience.

We love Twitter at Endpoints and want more people in biopharma to enjoy the benefits of it — even as a professional lurker.

Introducing Marco, our newsbot

Last August we quietly launched our viral newsbot@endpts. We recently named it Marco — constantly exploring BioTwitter.

It’s job is to:

  • Search for links in every tweet made in a known universe of thousands of BioTwitter accounts;
  • Calculate the velocity of each link shared;
  • If a link starts moving much faster relative to other links, it’s now trending;
    • Marco then visits the link itself and extracts the headline, author, and source. We want our own, independent information about the link.
  • Marco then tweets the link. It gives credit with a hat tip [h/t] to the account that it saw tweet the link first.

It’s that last part that forms the basis of this special report: who was the first person to report this news?

Marco has been reading BioTwitter 24 hours a day, 7 days a week for almost a a year now. Over this time we can aggregate the hat tips Marco doled out and come up with this exact list.

We guarantee if you follow a healthy segment of this list — you’re plugged into to heart of the link economy on BioTwitter.

What this list is not

Anytime you rank your friends and colleagues there’s bound to be hard feelings. So let me state for the record:

  • This is not a list of the best accounts to follow in BioTwitter. Many tweeps never post links and instead contribute with context and analysis. Marco is a few technological revolutions away from being able to understand when someone is being sarcastic or helpful, so it ignores text-only tweets. And that’s often the best part of Twitter.
  • This is not a who’s who list. There are plenty of those around and none of them do anything for the person who simply wants to be the best professional lurker on BioTwitter.
  • There are no value judgements here. This is a purely data-driven list. Yes, it’s our own propriety data and I’m not likely to divulge the exact manner in which we reduce the firehose of BioTwitter into a trickle. But we’re presenting the data as-is.


Biotech Twitter citizens most frequently credited with posting trending links first

Over 100 hat tips
JohnCendpts
FierceBiotech
BioStocks
bradloncar
AndyBiotech
adamfeuerstein
matthewherper
pharmalot
EricTopol
BentheFidler
FiercePharma

 

50 – 99 hat tips
Dereklowe
megtirrell
JacobPlieth
MaverickNY
crusadernz
ScripDonnaDC
BosBizDon
ldtimmerman
business
jonathanrockoff
Reuters_Health
3NT
CGrantWSJ
stefaniei
LifeSciVC

 

20 – 49 hat tips
ArmstrongDrew
BioRunUp
reutersBenHir
BiotechWorld
John_LaMattina
NatureNews
cardiobrief
Loftus
antonioregalado
JeanneWhalen
ivanoransky
ZacharyBrennan
CarolineYLChen
AKAarsalan
EmilyWFierce
DShaywitz
BlackSwanPharma
WrigleyTom
kristen_hallam
GideonGil
BioDueDiligence
ReutersBiz
CarlyHFierce
WSJbusiness
pharmagossip
TSTbiotech
jq1234t
scripnews
ZTracer
alexlash
arleneweintraub
IPOtweet
WSJAsia
bio_clouseau
FDALawyers
NPRHealth
ByJonGardner
charlesornstein
FDAadcomm
cafepharma
PDRennert
WSJ
lisamjarvis
edyong209
NEJM
juliaoftoronto
rplenge
deniseroland
lomu_j

 

At least 10 hat tips
techreview
BostonGlobe
Reuters
pknoepfler
WSJhealth
LauraLandroWSJ
portefeuillefun
ElyseTanouye
sdbn
andrew_ward1
TomBurtonWSJ
ActivistShorts
FayCortez
BiotechNews
dgmacarthur
drbachinsky
NatureBiotech
zbiotech
cells_nnm
Festivus159
iitoLifeScience
skathire
medtech_ma
US_FDA
genentech
DewDiligence
RNAiAnalyst
crayton_h
FT
voxdotcom
ScripMandy
carlzimmer
virginiahughes
dhovekamp42
AlecGaffney
NYTHealth
PhilSerafino
hmkyale
steveusdin1
fdalawblog
TheAtlantic
ScottKirsner
IAmBiotech
stemcellassays
TheStalwart
TradeHawk
BioBreakout
annaedney
politico
ddiamond
sxbegle
Frank_S_David
CMichaelGibson
MogulAzam
DrMiguelPerales
ScripEleanor
BioCentury
brentlsaunders
rleuty_biotech
michael_mezher
ProPublica
rickberke
GantosJ
DanBudwick
PharmaceuticBen
FierceMedDev
scientre
srqstockpicker
CNBC

 

At least 4 hat tips
joewalkerWSJ
ethanjweiss
23aloha
forbeshealth
GlobeRobW
EMA_News
sciencescanner
OpenOutcrier
MikeHuckman
big3bioBOS
daviesbj
Merck
mtmdphd
Drchik23
MedicalNews
SA_HealthInvest
dbsable
danprimack
annawmathews
guardianscience
MedicalNewsUSA
taralach
evaluatepharma
Ramsey_Baghdadi
westr
zerohedge
Liquid_Biopsy
Lin_ling_88
dsobek
Aiims1742
DrADKline
JNapodano
BioWorld
LizSzabo
BI_Science
TechCrunch
USATODAY
notSoJunkDNA
ideapharma
MartinShkreli
EvavonSchaper
maureenmfarrell
Carolynyjohnson
BioTerp
cbtadvisors
bmsnews
Alnylam
atticusMB
fundDuchenne
SashaDamouni
TimmermanReport
bbchealth
bmj_latest
FiercePharmAsia
biotechday
FDA_Drug_Info
PropThinker
NovartisScience
matt_levine
blsuth
FDAMedia
NewsfromScience
SudhanvaRaj
FiveThirtyEight
vlad33301
damiangarde
BlinkX90
sandiegoscience
Mykalt45
AdamSinger
ScottGottliebMD
DonWNicholson
GradyForrer
ASCO
DavidASteinberg
RPMReportMike
sloan_kettering
HumbleBioTrader
JAMA_current
ChillzTrading
SueDHellmann
jaybradner
daphnezohar
VikasDandekarET
cdweaver
bhmunos
SIRF_Report
mslopatto
michaelscally
michael_gilman
Dougallan1
princetongb
DrugPatentWatch
chrissyfarr
Zackfoot
maki_kitamura
jflier
LifeSciencesMkt
wilbanks
HelenBranswell
afrakt
rtnarch
Ogut_Ozgur
amandamicklus
walidgellad
smhedgecock
iBonanos
PearlF
jtozz
marynmck
DrJenGunter
Boston_Biotech
broadinstitute
ESchattner
picardonhealth
ScripLucie
cancerdocNYC
Xconomy
Novartis
hrana
BioWriterChik
NickPaulTaylor
WHO
pharmaconnect
mygershberg
gautamkollu
AnalystWire
EconSciTech
EPClinicalTrial
BioMedTracker
peterbachmd
CaulfieldTim
MarilynMann
John_Hempton
mbeisen
JohnPLeonardMD
charles_gaba
aleszubajak
BlackHawkTrader
JCMcCracken
BreakingNews
jodigralnick
eyeonfda
RobertLangreth
bernatolle
cellectis
KathyGiusti
RS_Flinn
ArthurCaplan
berthacoombs
Lymphoma_Doc
aaronecarroll
NIH
NYTScience
Street_Insider
DavidJuurlink
NatRevDrugDisc
actaestfabulaXX
23Chromz
EPVantage
FastCompany
MauriceOnTW
AnnemarieVtW
biotechbaumer
ewanbirney
JackWestMD
OncologyTimes
atlasventure
JPZaragoza1
BioWino
RNA_Biotech
JohnTuckerPhD
ColfaxCapital
simonbayly
NBCNewsHealth
fwpharma
InnatePharma
EricPFierce
thinkgenome
ACInvestorBlog
AlpineBV_Miller
HaertlG
ScripMikeWard
Roche
atulbutte
NatureMedicine


Get Endpoints News in your inbox

News reports for those who discover, develop, and market drugs. Join 16,000+ biopharma pros who read Endpoints News articles by email every day. Free subscription.

Quick Subscribe

You're subscribing to Endpoints News

John Carroll, Editor and Co-Founder

We produce two daily newsletters designed to give you a complete picture of what's important in biopharma.

Early Edition is a skimmable digest of original sources you need to see by ~7:15a ET, and our Main Edition is the daily chronicle of biotech, with every story inside the email ~11:55a ET.
2x/weekdays. Privacy policy